SwePub
Sök i LIBRIS databas

  Utökad sökning

(swepub) spr:eng pers:(Olsson T)
 

Sökning: (swepub) spr:eng pers:(Olsson T) > (2020-2024) > COVID-19 clinical o...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00008507naa a2200853 4500
001oai:gup.ub.gu.se/318901
003SwePub
008240528s2022 | |||||||||||000 ||eng|
009oai:DiVA.org:oru-100745
009oai:DiVA.org:umu-199108
009oai:DiVA.org:liu-187856
009oai:DiVA.org:uu-495215
009oai:lup.lub.lu.se:24ebd2ae-c532-4a55-b5b0-a6052d555472
009oai:prod.swepub.kib.ki.se:150531437
0247 a https://gup.ub.gu.se/publication/3189012 URI
0247 a https://doi.org/10.1002/acn3.516462 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-1007452 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1991082 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1878562 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4952152 URI
0247 a https://lup.lub.lu.se/record/24ebd2ae-c532-4a55-b5b0-a6052d5554722 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1505314372 URI
040 a (SwePub)gud (SwePub)orud (SwePub)umud (SwePub)liud (SwePub)uud (SwePub)lud (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Longinetti, E.u Karolinska Institutet,Karolinska Institute4 aut
2451 0a COVID-19 clinical outcomes and DMT of MS patients and population-based controls
264 c 2022-08-22
264 1b Wiley,c 2022
500 a Funding Agencies|Patient-Centered Outcomes Research Institute (PCORI) Award [MS-1511-33196]; Swedish MRC [2020-02700]; Swedish Research Council [2021-01418]; Swedish Research Council for Health, Working Life, and Welfare [2020-0115]; Knut and Alice Wallenbergs foundation [KAW 2020.0299_VC-2020-0040/VC-2021-0018]
520 a Objective: To estimate risks for all-cause mortality and for severe COVID-19 in multiple sclerosis patients and across relapsing-remitting multiple sclerosis patients exposed to disease-modifying therapies. Methods: We conducted a Swedish nationwide population-based multi-register linkage cohort study and followed all multiple sclerosis patients (n = 17,692 in March 2020), individually age-, sex-, and region-matched to five population-based controls (n = 86,176 in March 2020) during March 2020-June 2021. We compared annual all-cause mortality within and across cohorts, and assessed incidence rates and relative risks for hospitalization, intensive care admission, and death due to COVID-19 in relation to disease-modifying therapy use, using Cox regression. Results: Absolute all-cause mortality among multiple sclerosis patients was higher from March to December 2020 than in previous years, but relative risks versus the population-based controls were similar to preceding years. Incidence rates of hospitalization, intensive care admission, and death due to COVID-19 remained in line with those for all-cause hospitalization, intensive care admission, and mortality. Among relapsing-remitting patients on rituximab, trends for differences in risk of hospitalization due to COVID-19 remained in the demographics-, socioeconomic status-, comorbidity-, and multiple sclerosis severity-adjusted model. Interpretation: Risks of severe COVID-19-related outcomes were increased among multiple sclerosis patients as a whole compared to population controls, but risk increases were also seen for non-COVID-19 hospitalization, intensive care admission, and mortality, and did not significantly differ during the pandemic compared to pre-pandemic years. The risk conveyed by disease-modifying therapies was smaller than previously assumed, likely as a consequence of the possibility to better control for confounders.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi0 (SwePub)303022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Public Health, Global Health, Social Medicine and Epidemiology0 (SwePub)303022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng
653 a multiple-sclerosis
653 a register
653 a Neurosciences & Neurology
7001 a Bower, H.u Karolinska Institutet,Karolinska Institute4 aut
7001 a McKay, K. A.u Karolinska Institutet,Karolinska Institute4 aut
7001 a Englund, S.u Karolinska Institutet,Karolinska Institute4 aut
7001 a Burman, Joachim,d 1974-u Uppsala University,Uppsala universitet,Institutionen för medicinska vetenskaper,Experimentell neurologi4 aut0 (Swepub:uu)joabu293
7001 a Fink, K.u Karolinska Institutet,Karolinska Institute4 aut
7001 a Fogdell-Hahn, A.u Karolinska Institutet,Karolinska Institute4 aut
7001 a Gunnarsson, Martin,d 1973-u Örebro University,Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Neurology, Örebro University, Örebro, Sweden,Örebro Univ, Dept Neurol, Örebro, Sweden.4 aut0 (Swepub:oru)mign
7001 a Hillert, J.u Karolinska Institutet,Karolinska Institute4 aut
7001 a Langer-Gould, A.u Clinical and Translational Neuroscience, Southern California Permanente Medical Group, Kaiser Permanente, Los Angeles, USA,Clinical and Translational Neuroscience, Southern California Permanente Medical Group, Kaiser Permanente, Los Angeles, United States,Kaiser Permanente, Clin & Translat Neurosci, Southern Calif Permanente Med Grp, Los Angeles, CA USA.4 aut
7001 a Lycke, Jan,d 1956u University of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience,Department of Clinical Neuroscience, University of Gothenburg, Gothenburg, Sweden,Univ Gothenburg, Dept Clin Neurosci, Gothenburg, Sweden.4 aut0 (Swepub:gu)xlycja
7001 a Nilsson, Petrau Lund University,Lunds universitet,Neurologi, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Neurology, Lund,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)neur-pn8
7001 a Salzer, Jonatanu Umeå University,Umeå universitet,Neurovetenskaper,Umeå Univ, Dept Clin Sci, Neurosci, Umeå, Sweden.4 aut0 (Swepub:umu)jonser01
7001 a Svenningsson, A.u Karolinska Institutet4 aut
7001 a Mellergård, Johanu Linköping University,Linköpings universitet,Avdelningen för neurobiologi,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping,Linköping Univ, Dept Biomed & Clin Sci, Linköping, Sweden.4 aut0 (Swepub:liu)johme15
7001 a Olsson, T.u Karolinska Institutet,Karolinska Institute4 aut
7001 a Piehl, F.u Karolinska Institute4 aut
7001 a Frisell, T.u Karolinska Institutet,Karolinska Institute4 aut
7102 a Karolinska Institutetb Karolinska Institute4 org
7730 t Annals of Clinical and Translational Neurologyd : Wileyg 9:9, s. 1449-1458q 9:9<1449-1458x 2328-9503
8564 u https://doi.org/10.1002/acn3.51646y Fulltext
8564 u https://umu.diva-portal.org/smash/get/diva2:1701633/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://liu.diva-portal.org/smash/get/diva2:1691656/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://uu.diva-portal.org/smash/get/diva2:1730884/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u http://dx.doi.org/10.1002/acn3.51646x freey FULLTEXT
8564 8u https://gup.ub.gu.se/publication/318901
8564 8u https://doi.org/10.1002/acn3.51646
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-100745
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-199108
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-187856
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-495215
8564 8u https://lup.lub.lu.se/record/24ebd2ae-c532-4a55-b5b0-a6052d555472
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:150531437

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy